{"id":"W2946172582","doi":"10.1016/j.cgh.2019.05.019","title":"Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis","year":2019,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"National Center for Advancing Translational Sciences; National Institutes of Health; Ferring Pharmaceuticals; Crohn's and Colitis Foundation; Novo Nordisk; Teva Pharmaceutical Industries; Atlantic Healthcare; American College of Gastroenterology; Janssen Pharmaceuticals; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; Tillotts Pharma; Seres Therapeutics; Johnson and Johnson; AbbVie; Merck; GlaxoSmithKline; Takeda Pharmaceuticals U.S.A.; Pfizer; Shire; Bristol-Myers Squibb","keywords":"Medicine; Golimumab; Ulcerative colitis; Infliximab; Gastroenterology; Internal medicine; Vedolizumab; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002114378,0.0004810913,0.002535049,0.0006570453,0.0001780992,0.0008014655,0.0003626221,0.0009692397,0.001670229],"category_scores_gemma":[0.003666718,0.0003006989,0.0009627697,0.0005350214,0.000619425,0.001158984,0.0002557647,0.001547784,0.0003048074],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003694202,"about_ca_system_score_gemma":0.0003172186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003473438,"about_ca_topic_score_gemma":0.0003841379,"domain_scores_codex":[0.9990802,0.0004952911,0.00009021709,0.00008766686,0.00009137583,0.0001553088],"domain_scores_gemma":[0.9971443,0.001704536,0.0003588109,0.0001988542,0.0000902703,0.0005031782],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9346865,0.002479939,0.004613183,0.0002982554,0.0005198749,0.0001401742,0.00008471855,0.0007748933,0.01352987,0.0001215879,0.0001473868,0.04260351],"study_design_scores_gemma":[0.143191,0.7543433,0.08085746,0.0001154801,0.002527367,0.0005686928,0.0002012286,0.002101075,0.01398617,0.000402841,0.001626747,0.00007869072],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991165,0.007715546,0.0001174588,0.0001024342,0.0001128474,0.00003499004,0.00009254854,0.00001389463,0.0006453752],"genre_scores_gemma":[0.9978938,0.001283435,0.0001336056,0.00006888483,0.0002192482,0.00002642703,0.0001107855,0.000006380166,0.0002575781],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002535049,"threshold_uncertainty_score":0.01118201,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02940010932964247,"score_gpt":0.341193278886763,"score_spread":0.3117931695571205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}